

**EUROPEAN
CURRICULUM VITAE
FORMAT**



PERSONAL INFORMATION

Name	PEPE FRANCESCA FULVIA
Working Address	VIA G.B. PERGOLESÌ 33, MONZA (MB), 20900, ITALY
Mobile	
Fax	
E-mail	francescafulvia.pepe@irccs-sangerardo.it
Nationality	ITALIAN

WORK EXPERIENCE

- | | |
|--|--|
| • Dates | 06/09/2021 – present |
| • Name and address of the employer | Fondazione IRCCS San Gerardo dei Tintori, via G.B. Pergolesi, 33, MONZA |
| • Type of business or sector | Phase 1 Research Centre |
| • Occupation or position held | Medical Doctor - Oncologist |
| • Main activities and responsibilities | Clinical activity – Clinical Research Trials.
I've been involved in several clinical trials according to ICH GCP. Last GCP training performed on 23/09/2022 (ICH/GCP HCPs V2.1) |
| • Dates | 12/11/2020 – 05/09/2021 |
| • Name and address of the employer | Ospedale San Gerardo ASST-Monza, via G.B. Pergolesi, 33, MONZA |
| • Type of business or sector | Oncology Department |
| • Occupation or position held | Medical Doctor - Oncologist |
| • Main activities and responsibilities | Clinical activity – Clinical Research Trials
I've been involved in several clinical trials according to ICH GCP. Last GCP training performed on 01/09/2020 (ICH/GCP HCPs V2.1) |

EDUCATION AND TRAINING

- | | |
|--|---|
| • Dates | 01/11/2015 – 31/10/2020 |
| • Name and type of organisation providing education and training | Università degli Studi di Milano Statale – Università Milano Bicocca |
| • Principal subjects/occupational skills covered | Resident Doctor: Day Hospital activity in breast cancer – lung cancer – gastrointestinal&biliopancreatic cancer – skin cancer – genitourinary cancer – sarcomas |
| • Title of qualification awarded | Onco-specialist (70/70 cum laude) |
| • Dates | 11/2007 – 03/2015 |
| • Name and type of organisation providing education and training | Università degli Studi di Bari "Aldo Moro" – Faculty of Medicine |
| • Principal subjects/occupational skills covered | Medical Student |
| • Title of qualification awarded | Degree in Medicine & Surgery (110/110 cum laude) |
| • Dates | 01/2014 – 09/2014 |

- | | |
|---|--|
| <ul style="list-style-type: none"> • Name and type of organisation providing education and training • Principal subjects/occupational skills covered | <p>Université de Strasbourg – Faculté de Médecine</p> <p>Medical Student (ERASMUS project) – internship in Orthopedics, Neurology, Gynecology and Clinical Pharmacology</p> |
| <ul style="list-style-type: none"> • Dates • Name and type of organisation providing education and training • Principal subjects/occupational skills covered • Title of qualification awarded | <p>09/2002 – 06/2007</p> <p>Liceo Classico “Quinto Orazio Flacco” di Bari</p> <p>Student especially in cultural heritage conservation</p> <p>Secondary high school degree (90/100)</p> |
| <ul style="list-style-type: none"> • Dates • Name and type of organisation providing education and training • Principal subjects/occupational skills covered • Title of qualification awarded | <p>09/2002 – 06/2006</p> <p>Conservatorio di Musica “Niccolò Piccini” di Bari</p> <p>Violin player - Solfeggio</p> <p>Solfeggio degree (9.5/10)</p> |

PERSONAL SKILLS AND COMPETENCES

MOTHER TONGUE

ITALIAN

OTHER LANGUAGES

- | | |
|--|--|
| <ul style="list-style-type: none"> • Understanding • Speaking • Writing | <p>ENGLISH</p> <p>excellent</p> <p>good</p> <p>good</p> |
|--|--|

- | | |
|--|--|
| <ul style="list-style-type: none"> • Understanding • Speaking • Writing | <p>FRENCH</p> <p>B1</p> <p>B1</p> |
|--|--|

SOCIAL SKILLS AND COMPETENCES

Ability to work both independently and as part of a team.
Soft skills, Problem solving, team work skills.

TECHNICAL SKILLS AND COMPETENCES

Microsoft Office
PC Operation Systems: Windows, MacOSX

OTHER SKILLS AND COMPETENCES

SPORT: SWIM – JUDO

PUBLICATIONS

Pepe FF, Cazzaniga ME, Baroni S, Riva F, Cicchiello F, Capici S, Cogliati V, Maggioni C, Cordani N, Cerrito MG, Malandrin S. Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study. *BMC Cancer*. 2022 Sep 6;22(1):956. doi: 10.1186/s12885-022-10031-6. PMID: 36068484; PMCID: PMC9446532.

Cogliati V, Capici S, Pepe FF, di Mauro P, Riva F, Cicchiello F, Maggioni C, Cordani N, Cerrito MG, Cazzaniga ME. How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story. *Life (Basel)*. 2022 Mar 5;12(3):378. doi: 10.3390/life12030378. PMID: 35330128; PMCID: PMC8954717.

Cazzaniga ME, Capici S, Cordani N, Cogliati V, Pepe FF, Riva F, Cerrito MG. Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows. *J Clin Med*. 2022 Aug 12;11(16):4710. doi: 10.3390/jcm11164710. PMID: 36012949; PMCID: PMC9410269.

Capici S, Ammoni LC, Meli N, Cogliati V, Pepe FF, Piazza F, Cazzaniga ME. Personalised Therapies for Metastatic Triple-Negative Breast Cancer: When Target Is Not Everything. *Cancers (Basel)*. 2022 Jul 31;14(15):3729. doi: 10.3390/cancers14153729. PMID: 35954393; PMCID: PMC9367432.

Pierluigi di Mauro, Serena Capici, Viola Cogliati, Francesca Fulvia Pepe, Claudia Maggioni, Francesca Riva, Federica Cicchiello, Marina Elena Cazzaniga, Exceptional disease control with neratinib monotherapy in HER2-positive advanced breast cancer: A case report, *Current Problems in Cancer: Case Reports*, Volume 6, 2022, 100167, ISSN 2666-6219, <https://doi.org/10.1016/j.cpcr.2022.100167>.

Meazza Prina Marco, Gotuzzo Irene, Cazzaniga Marina Elena, De Bernardi Elisabetta, Cafaro Pietro, Capici Serena, Cogliati Viola, Pepe Francesca, et Al. Guerra Luca. (2023). Abstract P6-01-42: Baseline 18FDG-PET metabolic tumour volume (MTV) as a potential predictive factor of response to metronomic chemotherapy (mCHT) in HR+/HER2- metastatic breast cancer (MBC) patients (pts). Preliminary results of the metro-PET study. *Cancer Research*. 83. P6-01. 10.1158/1538-7445.SABCS22-P6-01-42.

Cordani Nicoletta, Mologni Luca, Piazza Rocco, Cogliati Viola, Pepe Francesca, Capici Serena, Di Bella Camillo, Jaconi Marta, Cerrito Maria Grazia, Villa Matteo, Tettamanti Pietro, Cavaletti, Guido, Lavitrano Marialuisa, Cazzaniga Marina. (2023). Abstract P1-13-21: Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells. *Cancer Research*. 83. P1-13. 10.1158/1538-7445.SABCS22-P1-13-21.

Trevisan B, Pepe FF, Vallini I, Montagna E, Amoroso D, Berardi R, Butera A, Cagossi K, Cavanna L, Ciccarese M, Cinieri S, Cretella E, De Conciliis E, Febbraro A, Ferraù F, Ferzi A, Baldelli A, Fontana A, Gambaro AR, Garrone O, Gebbia V, Generali D, Gianni L, Giovanardi F, Grassadonia A, Leonardi V, Sarti S, Musolino A, Nicolini M, Putzu C, Riccardi F, Santini D, Sarobba MG, Schintu MG, Scognamiglio G, Spadaro P, Taverniti C, Toniolo D, Tralongo P, Turletti A, Valenza R, Valerio MR, Vici P, Clivio L, Torri V, Cazzaniga ME; VICTOR Study Group. Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients. *Sci Rep*. 2023 Jul 28;13(1):12255. doi: 10.1038/s41598-023-39386-x. PMID: 37507480

Abstract PO4-04-10: Selection criteria for second-line treatments after Cyclin-dependent kinase 4/6 inhibitors failure in Hormone Receptor positive metastatic breast cancer patients: the preliminary experience of the HERMIONE-13 trial. May 2024 *Cancer Research* 84(9_Supplement):PO4-04-10-PO4-04-10. May 2024 84(9_Supplement):PO4-04-10-PO4-04-10 DOI:10.1158/1538-7445.SABCS23-PO4-04-10

Abstract: Abemaciclib + Aromatase Inhibitors (AIs) after first-line (1L) Fulvestrant (FUL) in hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC) patients (pts): still a chimaera? Final results of the multicentre Phase II Hermione-7 trial. Pepe FF 1, Borgogni V 2, Galimberti S 2, Ambroggi M 3, Beano A 4,

Berardi R 5, Bollina R 6 , Bullian P 7, Cariello A 8 , Coltelli L 9, Ferro A 10 , Fiorio E 11 , Moretti G 12 , Palumbo R 13 , Valerio MR 14 , Vici P 15 , Zustovich F 16 , Cicchiello F 17 , Capici S 1 and Cazzaniga ME 1,2

Abstract: Are there 18F-FDG PET/CT parameters able to predict tumour response to metronomic chemotherapy in metastatic breast cancer patients? Final results of the METRO-PET trial. G. Caspani,, I. Gotuzzo,, S. Capici,, V. Cogliati, F. F. Pepe, E. De Bernardi, F. Cicchiello, F. Riva, L. Monaco, F. Elisei, G. Mathoux, P. Cafaro, M. Meazza Prina, C. Landoni, L. Guerra, M. E. Cazzaniga

I authorize the processing of personal data contained in my curriculum vitae according to art. 13 of Legislative Decree 196/2003 and art. 13 GDPR 679/16